GlassScriptPhysician profile
Jesus F Lovera
NPI 1336246107
$26,547.38
in general payments reported to CMS, 2019-2025
51 companies · $3,120 in 2025
The $3,120 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,557 · 2020: $2,472 · 2021: $1,224 · 2022: $13K · 2023: $2,012 · 2024: $1,884 · 2025: $3,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,817 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,817.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $12,370.76 | 2019-2023 | Gamunex-C |
| Biogen, INC. | $2,151.07 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Abbvie INC. | $2,094.51 | 2021-2025 | |
| Emd Serono, INC. | $1,506.40 | 2019-2025 | Mavenclad |
| Tg Therapeutics, INC. | $984.07 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $948.48 | 2019-2025 | |
| Genzyme Corporation | $933.96 | 2019-2025 | |
| Amgen INC. | $612.21 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $492.97 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $486.38 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Alexion Pharmaceuticals, INC. | $402.17 | 2019-2025 | Ultomiris |
| Celgene Corporation | $392.29 | 2021-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $357.76 | 2019-2022 | |
| Csl Behring | $279.28 | 2019-2024 | Hizentra |
| Vanda Pharmaceuticals INC. | $227.82 | 2025 | Ponvory |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Lovera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.